Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ligustilide to prevention and treatment of breast cancer

A technology of ligustilide and breast cancer, applied in the direction of medical preparations containing active ingredients, organic active ingredients, drug combinations, etc., can solve the problem of ligustilide in breast cancer with less pharmacological activity research Pharmacological research is not deep and detailed enough to achieve the effect of improving transcriptional activity

Inactive Publication Date: 2016-06-08
SOUTHWEST UNIVERSITY
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Existing research reports have shown that ligustilide has strong pharmacological effects on cardiovascular and cerebrovascular systems, circulatory system and immune function, but these studies generally use mixtures containing ligustilide such as angelica oil or Chuanxiong oil, and ligustilide The pharmacological research of ligustilide is not deep and meticulous enough, and there are few studies on the pharmacological activity of ligustilide in breast cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ligustilide to prevention and treatment of breast cancer
  • Application of ligustilide to prevention and treatment of breast cancer
  • Application of ligustilide to prevention and treatment of breast cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] The synergistic effect of embodiment 1 ligustilide and tamoxifen

[0032] MDA-MB-231 cells were used in the experiment, and the concentration of ligustilide was set at 0, 10, 25, and 50 μmol / L. After 12 hours of pretreatment with ligustilide, they were mixed with 1, 2.5, and 5 μmol / L tamoxifen, respectively. Co-incubated for 72h, and obtained the experimental results by sulforhodamine B staining method (SRB), the results are as follows: figure 1 As shown, ligustilide and tamoxifen alone have almost no effect, but the inhibitory rate gradually increases with the concentration gradually increasing after synergistic use.

Embodiment 2

[0033] The synergistic effect of embodiment 2 Liguscarina A and tamoxifen

[0034] MDA-MB-231 cells were used in the experiment, and the concentration of chuanxionglide A was set from low to high to 0, 50, 100, and 150 μmol / L in turn. Fen co-incubated for 72h, and detected by sulforhodamine B staining method (SRB), the results were as follows: figure 2 As shown, the single citrolactone A has almost no effect on tamoxifen, and the inhibitory rate increases gradually with the concentration gradually increasing after combined use, which is the same as that of figure 1 The results were similar.

Embodiment 3

[0035] Example 3 Effect of ligustilide on ERα protein expression

[0036] MDA-MB-231 cells were used in the experiment. First, they were incubated with ligustilide at a concentration of 0, 10, 25, and 50 μmol / L for 48 hours, and the proteins were separated and collected for Western Blot experiments. The experimental results are as follows: image 3 As shown, as the concentration increased, the expression of ERα protein gradually increased.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of ligustilide to prevention and treatment of breast cancer. A research represents that the ligustilide has a certain inhibition effect on negative and positive breast cancer cells of an estrogen receptor alpha (ERalpha). Furthermore, existing breast-cancer-resisting drugs including tamoxifen and the like in the market mainly have effects on the positive breast cancer cells of the estrogen receptor alpha, but have very slight effects on the negative breast cancer cells of the estrogen receptor alpha; the research provided by the invention represents that the ligustilide can be used for increasing ERalpha protein expression of the breast cancer cells, and furthermore, the ligustilide and the tamoxifen are cooperated to realize the effect of preventing and treating the breast cancer.

Description

technical field [0001] The invention relates to a new application of ligustilide, in particular to the application of ligustilide in preventing and treating breast cancer. Background technique [0002] Breast cancer, also known as "milk stone" and "breast cancer", is one of the most common malignant tumors in women. According to data from Cancer Statistics in 2016, there were 1,685,210 new cases of cancer in the United States in 2015, and 595,690 patients would die of cancer. Among the female cancer incidence rates, breast cancer is the highest rate at 29%, and the mortality rate is second only to lung cancer. second. In China, the incidence of breast cancer is not optimistic. As early as 2013, the data from the China Cancer Registry Annual Report revealed that the average age of female breast cancer in my country was 48.7 years old, 10 years earlier than in Western countries. Among the high incidence cancers in women, breast cancer Cancer has surpassed lung cancer to becom...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/365A61P35/00A61K31/138
CPCA61K31/138A61K31/365A61K2300/00
Inventor 齐红艺马辉李莉
Owner SOUTHWEST UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com